88 search results for: Atopic Dermatitis
IL-4 Contributes to Systemic Type 2 Inflammation in AD
In this highlight video from the ADVENT AD symposium held at EADV’s 2024 Annual Meeting in Amsterdam, Dr. Stephan Weidinger discusses how IL-4 contributes to systemic type 2 inflammation in AD via several mechanisms, including T cell differentiation, B cell activation and IgE generation, and T regulatory cell inhibition.
Considerations for Disease Modification in AD
In this highlight video from the September 2024 ADVENT symposium at EADV’s Annual Meeting in Amsterdam, the Netherlands, Dr. Eric Simpson explores potential considerations when discussing the concept of disease modification and how early intervention might be disease modifying in AD.
How Does Protective Type 2 Immunity Become Harmful Type 2 Inflammation?
In this video soundbite from the March 2025 ADVENT symposium in Orlando, Florida, Dr. Eric Simpson explains how protective type 2 immunity can become dysregulated, leading to harmful type 2 inflammation.
KOL Video Interview – Dr Paula Luna
In this exclusive video interview, Dr Paula Luna discusses how disease modification can be defined in AD and how IgE may be used as a biomarker in AD.
KOL Video Interview – Dr Amy Paller
In this exclusive video interview, Dr Amy Paller discusses two topics: 1) The importance of CCL17 (TARC) as a biomarker in pediatric patients with AD, and 2) How IL-4 and IL-13 contribute to skin barrier dysfunction in AD.
Understanding Barriers to Advanced Systemic Therapy in AD
Dr. Jean-David Bouaziz highlights a study describing barriers to initiating advanced systemic therapy for AD at EADV 2025
Potential Biomarkers of Subclinical Control in AD Pathophysiology
Dr. Amy Paller describes potential biomarkers of subclinical control at EADV 2025
Clinical Utility of Biomarkers in the Management of AD
Dr. Amy Paller discusses the clinical utility of TARC measurements in AD management at EADV 2025
Unmasking Itch in Older Adults: Zooming in on the Unique Challenges
Dr. Butler emphasizes the increasing prevalence of chronic itch in the aging population and details the significant physical, psychological, and healthcare system burdens it imposes. He also explores why chronic pruritus is often under-recognized and challenging to diagnose due to its multifactorial etiologies
The Puzzle of Itch in Elderly Adults: Putting the Pieces Together
In this webinar, Dr. Butler highlights the complexities of chronic pruritus in older adults, highlighting its prevalence, burden, and the underlying pathophysiological mechanisms, including the role of type 2 inflammation
The Science Behind the Scratch: Pathophysiology of Age-Related Itch
Dr. Butler delves into the multifaceted biological mechanisms, including type 2 inflammation, that drive chronic pruritus in older adults. He explains how age-related changes contribute to epidermal barrier dysfunction, neuropathic damage, and immune decline, leading to chronic pruritus.
The Role of Type 2 Inflammation Across a Range of Pruritic Skin Diseases in Older Adults
Dr. Butler explores how type 2 inflammation is a common underlying mechanism in several prevalent chronic pruritic skin conditions affecting the elderly, such as CPUO, AD, BP, and PN
